Search

Displaying results 2991 - 3000 of 8694 in total
  1. Target

    Transient receptor potential cation channel subfamily V member 4

    go.drugbank.com/bio_entities/BE0009159
    TargetHumans

    In its inactive state, may sequester DDX3X at the plasma membrane. When activated, the interaction between both proteins is affected and DDX3X relocalizes to the nucleus (PubMed:29899501).

    Polypeptides: Transient receptor potential cation channel subfamily V member 4Synonyms: Vanilloid receptor-like channel 2, Vanilloid receptor-like protein 2
  2. Target

    B-cell antigen receptor complex-associated protein beta chain

    go.drugbank.com/bio_entities/BE0009680
    TargetHumans

    Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to

    Polypeptides: B-cell antigen receptor complex-associated protein beta chain
  3. Target

    Transient receptor potential cation channel subfamily M member 4

    go.drugbank.com/bio_entities/BE0009748
    TargetHumans

    May also be involved in pacemaking or could cause irregular electrical activity under conditions of Ca(2+) overload.

    Polypeptides: Transient receptor potential cation channel subfamily M member 4Synonyms: Long transient receptor potential channel 4
  4. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  5. Drug

    Isopropyl myristate

    go.drugbank.com/drugs/DB13966
    Approved

    [A178078] At the moment the primary usage for which isopropyl myristate is formally indicated is as the active ingredient in a non-prescription pediculicide rinse [A32333, L1964, L1966].

  6. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  7. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … Efanesoctocog alfa (BIVV001) is a recombinant factor VIII (FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and on-demand treatment and control of bleeding

  8. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. … [L48241,A232573] Pimavanserin was also under review as a potential treatment for dementia-related psychosis; however, as of April 2021, FDA approval has not been granted for this indication despite previous

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Miricorilant

    go.drugbank.com/drugs/DB16234
    Investigational

    Miricorilant is under investigation in clinical trial NCT03818256 (Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia and Recent

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  10. Drug

    Palifermin

    go.drugbank.com/drugs/DB00039
    ApprovedInvestigational

    Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.

    Categories: Detoxifying Agents for Antineoplastic Treatment